Factors predicting skeletal‐related events in patients with bone metastatic castration‐resistant prostate cancer. Issue 9 (27th December 2016)

• Record Type: Journal Article
• Authors: Klaassen, Zachary; Howard, Lauren E.; de Hoedt, Amanda; Amling, Christopher L.; Aronson, William J.; Cooperberg, Matthew R.; Kane, Christopher J.; Terris, Martha K.; Freedland, Stephen J.
• Is Part Of: Cancer. Volume 123:Issue 9(2017)
• Page Start: 1528
• Page End: 1535
• Publication Date: 2016-12-27
• Subjects: bone metastases -- bone pain -- metastatic castration‐resistant prostate cancer (mCRPC) -- prostate cancer -- skeletal‐related event (SRE); Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.30505
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : BACKGROUND: Skeletal‐related events (SREs) are common complications of bone metastatic castration‐resistant prostate cancer (mCRPC). To the authors' knowledge, there are limited data regarding which factors predict SREs. The authors identified risk factors for SREs in men with bone mCRPC using characteristics commonly available in the medical record. METHODS: Data from 454 patients with nonmetastatic CRPC were identified from 2 Veteran Affairs Medical Centers from 2000 through 2013. Among these men, 233 (51%) developed bone metastases during follow‐up and represented the study cohort. First occurrence of an SRE was abstracted from the medical records. A stepwise multivariable Cox model was used to select the strongest predictors of time to SRE. RESULTS: The median age of the patients at the time of diagnosis of bone mCRPC was 75 years (interquartile range, 68‐81 years), and there were 153 nonblack patients (66%). During follow‐up (median, 7.8 months [interquartile range, 2.9‐18.3 months]), 88 patients (38%) had an SRE. On univariable analysis, more recent year of metastasis (hazard ratio [HR], 0.91), prostate‐specific antigen doubling time of ≥9 months versus <9 months (HR, 0.50), and bone pain (HR, 3.34) were all found to be associated with SRE risk. On multivariable analysis, year of metastasis (HR, 0.93), biopsy Gleason score of 7 versus ≤6 (HR, 1.74), radiotherapy as the primary localized treatment versus none (HR, 2.33), and bone pain (HR, 3.64) were associated with SRE risk. The area under the curve for a multivariable model based upon these risk factors was 0.744. CONCLUSIONS: The authors identified several significant predictors of SREs among men with mCRPC. In particular, men with bone pain are at high risk of an SRE. If confirmed, future trials should focus on prolonging life and reducing SRE risk in patients with mCRPC with bone pain. Cancer 2017;123:1528–1535. © 2017 American Cancer Society . Abstract : In this study of 233 patients with bone metastatic castration‐resistant prostate cancer, men with bone pain are found to be at high risk of skeletal‐related events. If confirmed, future trials should focus on prolonging life and reducing the risk of skeletal‐related events among men with metastatic castration‐resistant prostate cancer with bone pain.